JP2021523126A - 蓄積した病理学的Ｔａｕタンパク質を低減する方法 - Google Patents

蓄積した病理学的Ｔａｕタンパク質を低減する方法 Download PDF

Info

Publication number
JP2021523126A
JP2021523126A JP2020561795A JP2020561795A JP2021523126A JP 2021523126 A JP2021523126 A JP 2021523126A JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP 2021523126 A JP2021523126 A JP 2021523126A
Authority
JP
Japan
Prior art keywords
months
accumulated
dspbn
pathological tau
tau protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523126A5 (https=
JPWO2019213245A5 (https=
Inventor
ディー． コピケ，リチャード
ディー． コピケ，リチャード
Original Assignee
ハフ イアー インスティテュート
ハフ イアー インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハフ イアー インスティテュート, ハフ イアー インスティテュート filed Critical ハフ イアー インスティテュート
Publication of JP2021523126A publication Critical patent/JP2021523126A/ja
Publication of JP2021523126A5 publication Critical patent/JP2021523126A5/ja
Publication of JPWO2019213245A5 publication Critical patent/JPWO2019213245A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020561795A 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法 Pending JP2021523126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666459P 2018-05-03 2018-05-03
US62/666,459 2018-05-03
PCT/US2019/030184 WO2019213245A1 (en) 2018-05-03 2019-05-01 Methods for reducing accumulated pathologic tau protein

Publications (3)

Publication Number Publication Date
JP2021523126A true JP2021523126A (ja) 2021-09-02
JP2021523126A5 JP2021523126A5 (https=) 2022-05-10
JPWO2019213245A5 JPWO2019213245A5 (https=) 2022-05-10

Family

ID=66530499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561795A Pending JP2021523126A (ja) 2018-05-03 2019-05-01 蓄積した病理学的Ｔａｕタンパク質を低減する方法

Country Status (4)

Country Link
US (1) US20210137861A1 (https=)
EP (1) EP3787750A1 (https=)
JP (1) JP2021523126A (https=)
WO (1) WO2019213245A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076332B2 (en) 2018-04-27 2024-09-03 The Regents Of The University Of California Treatment of lysosomal storage disorders
EP3784795A4 (en) 2018-04-27 2022-01-19 The Regents Of The University Of California INHIBITION OF LIPOFUSCIN AGGREGATION BY MOLECULAR TWEEZERS
CN115151250A (zh) * 2020-02-24 2022-10-04 欧博拉托股份有限公司 用于治疗癌症或肿瘤的组合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004045417A (ja) * 1993-12-21 2004-02-12 Innogenetics Nv Ｐｈｆ−タウに特異的なモノクローナル抗体、これらを分泌するハイブリドーマ、これらの抗体による抗原認識及びこれらの応用
JP2006517650A (ja) * 2002-11-07 2006-07-27 アプライド ニューロソリューションズ 軽度認知障害（ｍｃｉ）を有する対象がアルツハイマー病を発症するか否かを予測する方法
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
CA2772097C (en) * 2009-08-24 2019-04-30 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
US20180256756A1 (en) * 2015-09-18 2018-09-13 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
CN110248650A (zh) * 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004045417A (ja) * 1993-12-21 2004-02-12 Innogenetics Nv Ｐｈｆ−タウに特異的なモノクローナル抗体、これらを分泌するハイブリドーマ、これらの抗体による抗原認識及びこれらの応用
JP2006517650A (ja) * 2002-11-07 2006-07-27 アプライド ニューロソリューションズ 軽度認知障害（ｍｃｉ）を有する対象がアルツハイマー病を発症するか否かを予測する方法
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
JP2017119722A (ja) * 2011-10-03 2017-07-06 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FREE RADICAL BIOLOGY & MEDICINE, vol. 108, JPN6023014222, 2017, pages 627 - 643, ISSN: 0005210847 *
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2016, JPN6023014221, 2016, pages 1 - 15, ISSN: 0005210846 *

Also Published As

Publication number Publication date
US20210137861A1 (en) 2021-05-13
WO2019213245A1 (en) 2019-11-07
EP3787750A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
CN110248650A (zh) 用于增强突触发生和神经突发生的方法
US20100247517A1 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
US10925858B2 (en) S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
WO2017087962A1 (en) Methods for treating alzheimer's disease and related disorders
CN112912141A (zh) 用于树突棘生成的肌成束蛋白结合化合物
JP2021523126A (ja) 蓄積した病理学的Ｔａｕタンパク質を低減する方法
JP2026041805A (ja) 認知機能低下患者におけるアミロイドβモノマーレベルを減少させる方法
CA2920073A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
CN116870027B (zh) 手性钴纳米粒子在制备治疗阿尔兹海默症药物中的应用
AU2019350443A1 (en) Combination of acetylcholinesterase inhibitor and 5-HT4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
US20140206763A1 (en) Phenylbutyrate for treatment of sporadic inclusion-body myositis and disorders relating to autophagy impairment or amyloid beta 42 accumulation
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
Berkoz The role of oxidative stress in Alzheimer’s disease
WO2011039394A2 (es) Utilización de la gimnodimina, análogos y derivados para el tratamiento y/o la prevención de enfermedades neurodegenerativas relacionadas con tau y b-amiloide
Zhang et al. The GLP-1/GIP dual receptor agonist DA5-CH is superior to Exendin-4 in protecting neurons in the 6-OHDA rat Parkinson Model
WO2024165757A1 (en) Oral phenylbutyrate for treatment of human 4-repeat tauopathies
KR20250178241A (ko) Hapln1을 유효성분으로 포함하는 노인성 퇴행성 뇌질환 예방 또는 치료용 조성물
HK40012341A (en) Methods for enhancing synaptogenesis and neuritogenesis
HK40083593A (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
CN102349908A (zh) 右丙亚胺在制备治疗神经退行性疾病药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205